ReviewIJID regions2025
The Global Fund's Bangladesh program.
Review in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Escalating trends and burden of HIV among men who have sex with men in Bangladesh: A newly emerging concentrated epidemic.Biosafety and health · 2026Article
- Visceral leishmaniasis & HIV co-infection in Bangladesh: Investigating prevalence and policy recommendations.Journal of infection and public health · 2026Article
- Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects.Archives of microbiology · 2026Review
- Pulmonary versus extrapulmonary tuberculosis among diagnosed tuberculosis cases in Bangladesh: Evidence from a systematic review and meta-analysis.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Review
- An update on bloodborne viruses among people who inject drugs in South Asia.Harm reduction journal · 2026Review
- Malaria in Bangladesh, 2000-2025: Navigating the Headwinds From Control to Elimination.Health science reports · 2026Article
- The HIV/AIDS landscape in Bangladesh: an updated review of epidemiological trends, prevention gaps, and key population engagement.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Global Fund program, launched in 2002, focuses on combating HIV/AIDS, tuberculosis (TB), and malaria. To date, it has mobilized over US$ 65 billion across 120 countries, contributing to saving more than 65 million lives. In Bangladesh, the Global Fund has played a pivotal role in expanding treatment coverage, enhancing case detection, and strengthening prevention efforts. Despite notable progress, significant challenges persist, particularly among high-risk populations such as people who inject drugs, sex workers, and transgender individuals. These groups face stigma and limited access to healthcare, both of which hinder disease control. Additionally, drug resistance presents a growing threat to the control of malaria and TB. Looking ahead, continued support from the Global Fund will be critical, particularly in scaling up diagnostic infrastructure, promoting community-led interventions, and enhancing cross-border collaboration. These efforts are essential to ensuring sustained progress and achieving the long-term goal of eliminating HIV, TB, and malaria in Bangladesh. Effective coordination among government agencies, non-governmental organizations, and international donors will be essential to ensure the success of these initiatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.